Forever Labs, the parent company of SuperShot® PRP, will utilize DataBiologics to track outcomes for their innovative PRP process that allows autologous extracellular vesicles to be isolated.


SuperShot PRP is a centrifugation process that adds only one more step to your PRP procedure. Utilizing the physics of a documented two phase aqueous system, SuperShot PRP allows for the isolation of lipid rich extracellular vesicles via sizing.

Only a 1-minute spin for the
most complete PRP.

Watch the video to learn more about SuperShot PRP and how a 1-minute spin provides the most complete PRP treatment.

Frequently asked questions

What is SuperShot® PRP?

SuperShot® PRP is a process that concentrates the plasma EVs in PRP. By performing one additional spin of the platelet-poor plasma (PPP), SuperShot® enables the precipitation of low-density lipid-based EVs. All PRP contains EVs (including exosomes). 

Using SuperShot® PRP in the PRP process increases the content of EVs by concentrating them.  

Why doesn’t the standard PRP process concentrate EVs?

EVs are not dense enough to be isolated by clinical centrifuges, which typically spin at speeds of 1000-5000 RPM. To precipitate EVs by centrifugation alone, speeds of >100,000 RPM are required, and it takes several hours. Standard PRP contains EVs, but they are not concentrated above the patient’s basal plasma levels by the normal PRP process.

How does SuperShot® work?

SuperShot employs a physics technique to change the dynamics of plasma centrifugation. The addition of polyethylene glycol (PEG) and a high-weight Dextran (Dex) to plasma creates an aqueous two-phase system that decreases the solubility of low-density lipids (such as EVs). The EVs can then readily be pelleted at tabletop centrifuge speeds.

Is SuperShot® solution included in the PRP?

No. The PEG/Dex in SuperShot® solution remains in the depleted PPP, which is discarded. Both the PEG and Dex remain soluble in the PPP. Only the pelleted EVs are added to the PRP.

Is SuperShot® PRP autologous?

Yes. The SuperShot® process concentrates EVs that are in the patient’s plasma. Just like concentrating platelets, SuperShot® concentrates what is already in the patient’s blood.

Are plasma extracellular vesicles a therapeutic component of PRP?

This is an open question. PRP is relatively new itself, and its therapeutic components are still being elucidated. However, there is pre-clinical evidence that suggests that plasma-derived EVs (which include exosomes) have therapeutic value. Here are some recent studies of plasma EVs in animals:

  • Exosomes derived from human platelet-rich plasma prevent apoptosis induced by glucocorticoid-associated endoplasmic reticulum stress in rat osteonecrosis of the femoral head via the Akt/Bad/Bcl-2 signal pathway:

Could the therapeutic effect of plasma extracellular vesicles vary between patients?

Almost certainly. As mentioned above, the individual therapeutic components of PRP itself have not been well-established; however, there is evidence that the effect of PRP varies between patients. If plasma EVs underpin the effects of PRP, then this effect would be expected to vary between patients as well.

As all physicians that employ PRP are aware, different PRP systems and processes result in different PRP preparations. PRP preparations vary in concentrations of leukocytes, RBCs, platelets, proteins, etc., and these vary within the same preparation between patients.

The SuperShot® PRP process enables the concentration of EVs in the PRP preparation. 

Most physicians that use PRP clinically believe that more clinical trials to test applications and various PRP preparations will improve PRP therapy. The new ability to concentrate the EV component in PRP preparation should warrant consideration in clinical investigations as well.  

Why are plasma extracellular vesicles interesting?

EVs are released by cells that efficiently transfer their molecular cargo to other cells. Plasma is rich in exosomes, a type of EV, and it is known that exosomes mediate many physiological functions, including inflammation, angiogenesis, and wound healing. Exosomes contain non-coding RNAs (such as microRNAs) that have potent effect upon acceptor cells that take up the exosomes. 

Unlike proteins that are used by cells as functional molecules, non-coding RNAs in exosomes can modulate gene expression in acceptor cells. For these reasons, exosomes have generated considerable clinical interest over the past decade, with hundreds of clinical trials testing their therapeutic application

What is the regulatory status of SuperShot® PRP?

PRP is considered a blood product, per the FDA guidance “Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use”; July 2020, Section V.A, pg. 22: “…for example, platelet rich plasma (PRP, blood taken from an individual and given back to the same individual as platelet rich plasma) is not an HCT/P under 21 CFR Part 1271 because it is a blood product.”

SuperShot® PRP is a PRP preparation, according to the FDA’s guidance as: 
  1. It is a blood product,
  2. It is autologous
  3. It is removed from an individual and implanted into the same individual in the same surgical procedure
  4. It does not include intervening processing steps beyond rinsing, cleansing, sizing, or shaping, and
  5. It raises no additional risks of contamination and communicable disease transmission beyond that typically associated with surgery.

Does the SuperShot® isolated fraction contain exosomes?

Yes. The plasma is rich in exosomes, and exosomes are EVs that range between 30-150nm in diameter. Many analyses have demonstrated that the SuperShot® isolated fraction is rich in exosomes; indeed, they may be the most abundant EV present. However, there are other EVs isolated by SuperShot® as well, some ranging up to 450nm in size. As an example, some of these EVs are likely platelet-derived microvesicles which are larger than exosomes. Some EVs are created by different processes, however the characterization of EVs is often dependent upon the context in which they are studied.

Exosomes are some of the best studied EVs, and they constitute a large portion, if not the majority of EVs isolated in the SuperShot® fraction. For this reason, we often speak to the exosomes isolated by SuperShot®. That said, the SuperShot® process isolates all low-density EVs from the PPP.  

The SuperShot® PRP Difference

In a standard PRP preparation, whole blood is centrifuged into three components, separated by density: red blood cells, Platelet-Rich Plasma, and Platelet-Poor Plasma.

In SuperShot PRP, the Platelet-Poor Plasma is centrifuged one additional time using the SuperShot PRP patent-pending aqueous two-phase system, that precipitates a low-density lipid-rich extracellular fraction from the Plasma.

The extracellular fraction isolated by SuperShot® is added to the PRP, resulting in a more complete PRP.

The SuperShot PRP Difference

SuperShot® : Simple, Self & Safe

SuperShot PRP is quick and easy. With just one additional 1-minute spin, SuperShot PRP adds hundreds of billions of therapeutic extracellular molecules (and the important signaling molecules they contain within) to your PRP.

SuperShot PRP leverages the patient’s own biology. Isolation of the low-density extracellular fraction from the patient's plasma results in a more complete PRP.

SuperShot PRP does not use allogeneic or xeno-sourced materials. Supershot PRP is 100% autologous, which means no risk from donor pathogens, unknown sourcing, unproven allogeneic biologics, or immuno-rejection.


More Extracellular Vesicles

Low-density extracellular vesicles (EVs) are isolated from platelet-poor plasma with the SuperShot® PRP process.

Distinct types of EVs are isolated and added to PRP. 845 billion unique extracellular particles (169B/mL) with an average diameter of 130nm were isolated from 5cc of platelet- poor plasma by the SuperShot® PRP process.

IMAGE: Extracellular fraction isolated from platelet-poor plasma by SuperShot® PRP analyzed by the NanoSight imaging device.

More MicroRNAs

Extracellular vesicles in the plasma carry potent biologically active molecules including non-coding microRNAs. MicroRNAs are critical signaling components during wound healing, tissue regeneration, and neo-vascularization.

The SuperShot® PRP process enables the isolation of lowdensity EVs, increasing their concentration in PRP, and the important microRNAs they carry within.

IMAGE: MicroRNAs identified in PRP or SuperShot® processed PRP via single-end sequencing on an Illumina Hiseq 2500. PureSpin® PRP centrifugation system was used to process peripheral whole blood from a healthy donor.


Extracellular microRNAs isolated using the SuperShot® PRP process target numerous key gene pathways.

IMAGE: Gene pathways targeted by microRNAs in the extracellular fraction isolated from platelet-poor plasma by SuperShot® PRP via single-end sequencing.



Stem Cell Support

The Extracellular Fraction isolated using the SuperShot® PRP process from Platelet- Poor Plasma stimulated Mesenchymal Stem Cell growth in 5 days of cell culture, indicating that the extracellular fraction isolated by SuperShot® PRP supports stem cell growth.

IMAGE: Bone marrow Mesenchymal Stem Cells cultured for 5 days in control conditions, or with the addition of the Extracellular Fraction isolated from platelet-poor plasma produced from the SuperShot® PRP process. A dual spin PRP centrifugation system was used to process peripheral whole blood from a healthy donor.

Autologous & Appropriate

The Extracellular Fraction isolated by the SuperShot PRP process is autologous and collected and used at point-of-care, not shipped, or stored before use.

Allogeneic products are damaged by freezing and lyophilization. Aside from introducing serious risks such as infection from prions or viruses, allogeneic products are functionally degraded by processing and storage.

IMAGE: Extracellular Fraction isolated from platelet poor plasma by SuperShot® PRP vs. allogeneic mesenchymal stem cell derived product, analyzed by the NanoSight imaging device. SuperShot® EF included 78,000,000,000 particles/mL; MSC product included 540,000,000 particles/mL.


The leading allogeneic mesenchymal stem cell product contained just 0.6% of the extracellular vesicles isolated by SuperShot PRP from 5cc of Platelet-Poor Plasma.

IMAGE: MicroRNAs identified in extracellular fraction isolated from platelet poor plasma by the SuperShot® PRP process vs. allogeneic mesenchymal stem cell derived product via single-end sequencing on an Illumina Hiseq 2500. A dual spin PRP centrifugation system was used to process peripheral whole blood from a healthy donor.